Peter Hutt

Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA.

Placon Therapeutics, Inc. develops novel platinum therapies. The private company is based in Watertown.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It offers ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company is headquartered in San Diego, CA.

Life Line Screening Holdings LLC is a private company that provides annual screenings for risks of cardiovascular disease, stroke, and other chronic diseases. The company is based in Austin, TX. The company's screenings are designed by doctors and administered by trained professionals to help detect hidden health issues before they become a serious problem. The company offers a high sensitivity c-reactive protein test (hs-crp test) to detect inflammation in the body, which can indicate the presence of atherosclerosis. The company also provides type 2 diabetes test and diagnosis services. The company was founded in 1993 and the CEO is Matt Miller.

Life Line Screening of America Ltd. provides community based preventive health screenings services. It provides testosterone deficiency screening, vitamin D, heart disease, lung cancer, atrlal fibrillation, thyroid disease and prostate cancer screening . The company was founded by Colin Scully and Timothy Phillips in 1996 and is headquartered in Austin, TX,

Celera Corp. provides medical diagnostics services. It offers disease management solutions through a combination of tests and services based on genetics discovery platforms. Celera was founded in 1998 and is headquartered in Alameda, CA.

ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.

Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.

Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Atelerix Life Sciences, Inc. is a pharmaceutical company that is developing a new drug, ATLX-0199, to address the unmet need of opioid-induced respiratory depression (OIRD) in surgical patients. The company is based in Charlottesville, VA. Atelerix Life Sciences was founded by David G. Kalergis, Benjamin Gaston, James Bates, and Stephen Lewis, with David G. Kalergis serving as the CEO since incorporation. The current drug for OIRD, Naloxone, is problematic and used infrequently because it reverses pain relief. ATLX-0199 safely stimulates opioid-depressed respiratory drive without interfering with opioid-induced analgesia.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.

Pendulum Therapeutics, Inc. engages in the development of therapeutics and diagnostics that target the human microbiome to improve the lives of patients suffering from various diseases. Its product pipeline includes WBF-011, WBF-020, WBF-012, and WBF-014.. The company was founded by Colleen Cutcliffe, John Eid, and James Bullard in 2012 and is headquartered in San Francisco, CA.

Pendulum Therapeutics, Inc. engages in the development of therapeutics and diagnostics that target the human microbiome to improve the lives of patients suffering from various diseases. Its product pipeline includes WBF-011, WBF-020, WBF-012, and WBF-014.. The company was founded by Colleen Cutcliffe, John Eid, and James Bullard in 2012 and is headquartered in San Francisco, CA.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

CereHealth Corp. engages in the production of brain imaging software by utilizing high resolution gamma cameras. It specializes in Single-Photon Emission Computed Tomography (SPECT) & Positron Emission Tomography (PET). The company is headquartered in Littleton, CO.

ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutic Products, Inc. develops novel products to treat debilitating and fatal diseases. The company was founded by Dennis B. Farrar and Mahendra S. Rao in 2004 and is headquartered in Salt Lake, UT.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Pendulum Therapeutics, Inc. engages in the development of therapeutics and diagnostics that target the human microbiome to improve the lives of patients suffering from various diseases. Its product pipeline includes WBF-011, WBF-020, WBF-012, and WBF-014.. The company was founded by Colleen Cutcliffe, John Eid, and James Bullard in 2012 and is headquartered in San Francisco, CA.

Proterris, Inc. manufactures applications of low-dose carbon monoxide. It develops carbon monoxide for delayed graft function in renal transplant recipients and idiopathic pulmonary fibrosis. The company was founded by Jeffrey Wager and Joseph Wager and is headquartered in Boston, MA.

CereHealth Corp. engages in the production of brain imaging software by utilizing high resolution gamma cameras. It specializes in Single-Photon Emission Computed Tomography (SPECT) & Positron Emission Tomography (PET). The company is headquartered in Littleton, CO.

Life Line Screening of America Ltd. provides community based preventive health screenings services. It provides testosterone deficiency screening, vitamin D, heart disease, lung cancer, atrlal fibrillation, thyroid disease and prostate cancer screening . The company was founded by Colin Scully and Timothy Phillips in 1996 and is headquartered in Austin, TX,

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

Colabs International Corp. is a pharmaceutical company that develops formulations and medicines. The company’s targeted epidermal-drug delivery system which is identified as QuantaSphere Technology for cosmeceuticals, fragrances, antibacterial, anti-viral sanitizers, cleaners, and topical pharmacology. It also offers sunscreen, pest repellents, and sanitizers, soap distribution for the firm’s Klenskin products internationally. Its QuantaSphere Technology formulations provide proprietary, epidermal therapeutic effects and also blends consumer needs for a healthy lifestyle with targeted, eco-friendly, multi-tasking products. The company was founded by Laura Cohen and Lisa Leblanc on August 5, 2008 and is headquartered in Huntington Beach, CA.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Longwood Fund Management LLC (Longwood Fund Management) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Dipp and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT.

Life Line Screening of America Ltd. provides community based preventive health screenings services. It provides testosterone deficiency screening, vitamin D, heart disease, lung cancer, atrlal fibrillation, thyroid disease and prostate cancer screening . The company was founded by Colin Scully and Timothy Phillips in 1996 and is headquartered in Austin, TX,

Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It offers ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company is headquartered in San Diego, CA.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Life Line Screening Holdings LLC is a private company that provides annual screenings for risks of cardiovascular disease, stroke, and other chronic diseases. The company is based in Austin, TX. The company's screenings are designed by doctors and administered by trained professionals to help detect hidden health issues before they become a serious problem. The company offers a high sensitivity c-reactive protein test (hs-crp test) to detect inflammation in the body, which can indicate the presence of atherosclerosis. The company also provides type 2 diabetes test and diagnosis services. The company was founded in 1993 and the CEO is Matt Miller.

Life Line Screening of America Ltd. provides community based preventive health screenings services. It provides testosterone deficiency screening, vitamin D, heart disease, lung cancer, atrlal fibrillation, thyroid disease and prostate cancer screening . The company was founded by Colin Scully and Timothy Phillips in 1996 and is headquartered in Austin, TX,

CereHealth Corp. engages in the production of brain imaging software by utilizing high resolution gamma cameras. It specializes in Single-Photon Emission Computed Tomography (SPECT) & Positron Emission Tomography (PET). The company is headquartered in Littleton, CO.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It offers ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company is headquartered in San Diego, CA.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

InCube Ventures Partners LLC (InCube Ventures) is a venture capital firm founded in 2008 by Mir Imran. The firm is headquartered in San Jose, California.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutics, Inc. engages in developing adult stem cell therapies to treat debilitating disease of the central nervous system. Its product, Q-Cells will undergo first-in-human trials for ALS. The firm’s therapeutic strategy is intended to restore the normal activity of neurons by providing the support functions present in healthy central nervous system tissue. The company was founded by Dennis B. Farrar, Mahendra S. Rao, Mani Ramaswami, and Steven Goldman in March 2002 and is headquartered in Salt Lake City, UT.

Q Therapeutic Products, Inc. develops novel products to treat debilitating and fatal diseases. The company was founded by Dennis B. Farrar and Mahendra S. Rao in 2004 and is headquartered in Salt Lake, UT.

Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.